PharmaceuticalsOctober 19, 2026Daniel Szawarnoga, Joanna Fojcik, Michał Kamil Górski et al.
Treatment-resistant depression (TRD) remains one of the most clinically challenging forms of depressive disorders. In many patients, reduction in symptom severity does not translate into full functional recovery; therefore, assessment of treatment effectiveness should also include health-related quality of life (HRQoL). Objective: The aim of the study was to compare changes in HRQoL in patients...
PharmaceuticalsJuly 19, 2025Daniel Szawarnoga, Joanna Fojcik, Michał Górski et al.1 citation
Background: Insomnia, as one of the most common sleep disorders, is a significant health problem, especially among patients suffering from drug-resistant depression. Problems related to the quality of sleep in that population can significantly affect the effectiveness of treatment and quality of life, which is why it is necessary to search for effective therapeutic interventions in this area....